Effect of adjunctive metformin on recurrence of non-DM colorectal cancer

Effect of adjunctive metformin on recurrence of non-DM colorectal cancer stage II high-risk/ III colorectal cancer: Open-label randomized controlled

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

CRIS

Registry ID

KCT0004236

Enrollment

593

Registered

2019-08-23

Start date

2016-07-08

Completion date

Unknown

Last updated

2020-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : This study is an open label randomized controlled clinical trial to examine the effect of adjunctive metformin on recurrence of non-DM colorectal cancer stage II high-risk/ III colorectal cance

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: A. Colorectal cancer stage II high-risk/ III colorectal cancer patients B. Age range of 20-80 C. Non-diabetes patients D. Patients who have chemotherapy-tolerable general condition E. Patient who agree with the study

Exclusion criteria

Exclusion criteria: A. Patients who had diabetes before diagnosis of colorectal cancer, B. Insufficient medical records C. History of other cancer within 5 years D. Serious combined diseases (kidney, lung, liver, and infectious diseases or sepsis) E. Other inadequate medical conditions for clinial trials

Design outcomes

Primary

Measure	Time frame
recurrence rate	—

Secondary

Measure	Time frame
5 years survival;adverse effect;recurrence rate of colorectal polyp	—

Countries

Korea, Republic of

Contacts

Public ContactTae Il Kim

Yonsei University Health System, Severance Hospital

Outcome results